One Biologic Decision, Two Diseases Both Wanting to Go First
A single patient with an active Crohn's flare and a newly diagnosed eosinophilic esophagitis, and one drug class carrying a real, if rare, association with the exact disease he needs controlled first. The disagreement is whether to sequence the two decisions or make them at once.
Julian A., 24, has managed Crohn's disease since he was 19, mostly successfully, on azathioprine alone — until this flare, his first clearly biologic-worthy one, brought him back with worsening abdominal pain and stool frequency his maintenance regimen isn't controlling. In the middle of working up the flare, a separate problem surfaced: a food-impaction visit last month led to an endoscopy that found eosinophilic esophagitis, unrelated in mechanism to his Crohn's but now sitting on the same treatment-planning table. Dupilumab is the best-evidenced drug available for his EoE. It is also a drug with a real, if rare, association worth naming directly: case reports describe new-onset or exacerbated colitis in patients started on dupilumab for other indications, including Shimodaira and colleagues' 2021 report describing a picture that mimicked ulcerative colitis on biopsy in a young man treated for atopic dermatitis.
That association is documented at the case-report level, not established by controlled data, and the patients in those reports mostly didn't have preexisting active IBD the way Julian does right now. Whether the same signal would behave differently — better, worse, or the same — in someone whose gut is already actively inflamed isn't something the existing case reports can answer, because none of them describe that specific starting point. Meanwhile his Crohn's flare needs a biologic decision on its own, independent of the EoE question entirely, and the team has to decide whether these are one decision or two: pick a single drug meant to cover both diseases, or control the gut first with something unambiguously safe for it, and revisit the esophagus once that's settled.
Julian's own account of the past year adds a practical complication worth naming directly: he lost his job during a rough stretch of this same flare and is currently between insurance plans, covered for now through a state program with a narrower formulary than his prior commercial plan carried. That doesn't change which drug is medically right for him, but it does mean the team needs to confirm coverage for whichever biologic gets chosen before treating today's decision as settled — a real-world constraint sitting alongside the clinical one, not a detail that can wait until after the prescription is written.
Two active diseases, one drug the literature can't quite clear
I don't want to start dupilumab while his Crohn's is actively flaring. There are real, if rare, case reports of new-onset or worsening colitis on this drug — Shimodaira's group described one that mimicked ulcerative colitis outright — and none of those reports describe a patient whose gut was already actively inflamed the way his is right now.
I'd push back on treating a handful of case reports in patients without preexisting IBD as disqualifying for a patient who has it. Julian has already had one food impaction, and dupilumab is the only medication with actual approved efficacy for what caused it. Leaving that untreated has its own real cost while we wait out an uncertain signal.
I take the case reports seriously — I’m not dismissing them. I’m saying they don’t tell us what happens in someone who already has active IBD, because none of the reported cases started from that point, in either direction.
I don't think this needs to be one drug covering both diseases. His Crohn's flare has its own biologic options that are unambiguously gut-selective and don't carry this open question at all — start there, get him into remission, and the dupilumab decision gets easier because the one variable the literature can't currently speak to, active preexisting IBD, is no longer in the picture.
That's not a way of avoiding the dupilumab question — it's still coming, once his gut is controlled. It just means we're not making two uncertain decisions on top of each other when one of them doesn't have to happen today.
Agreed: start vedolizumab induction for the Crohn's flare now, manage his EoE symptomatically with dietary modification and a PPI trial in the interim, and revisit dupilumab once remission is achieved.
Not agreed, and named explicitly rather than resolved by the sequencing plan:
The allergist would move to dupilumab promptly, arguing that remission itself removes the specific uncertainty that justified waiting, and further delay has its own cost to his esophagus.
The gastroenterologist would want a longer period of demonstrated stability — not just remission at one visit — before adding a drug with any open question at all, given how new his biologic response still is.
How long is 'long enough' remission before dupilumab becomes reasonable to add was raised directly and left unanswered — a real second decision point, not a detail to be filled in automatically once the first one resolves.